Back to Search
URSULA MATULONIS, MD
MD
Medical Oncology Physician
NPI: 1992870638IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
72597(MA)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
ALBANY MEDICAL COLLEGE OF UNION UNIVERSITY
Class of 1987
Research & Publications (20)
Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.
PMID 19058838·Gynecol Oncol·2009
3-trial
Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
PMID 19001330·J Clin Oncol·2008
3-trial
Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer.
PMID 16566993·Gynecol Oncol·2006
3-trial
Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.
PMID 16376743·J Pain Symptom Manage·2005
3-trial
A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.
PMID 14599858·Gynecol Oncol·2003
3-trial
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen.
PMID 16806439·Gynecol Oncol·2006
3-trial
Comparison of the quality of life of early and advanced stage ovarian cancer survivors.
PMID 19481244·Gynecol Oncol·2009
4-observational
Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial.
PMID 19552597·J Altern Complement Med·2009
2-rct
Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer.
PMID 19047092·Clin Cancer Res·2008
8-other
Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.
PMID 18502492·J Allergy Clin Immunol·2008
8-other
Ovarian cancer. Clinical practice guidelines in oncology.
PMID 18926089·J Natl Compr Canc Netw·2008
6-review
Acupuncture for chemotherapy-induced leukopenia: exploratory meta-analysis of randomized controlled trials.
PMID 17309808·J Soc Integr Oncol·2007
1-meta
A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies.
PMID 17126894·Gynecol Oncol·2007
3-trial
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
PMID 18024865·J Clin Oncol·2007
3-trial
Negative laparoscopy is highly predictive of negative second-look laparotomy following chemotherapy for ovarian, tubal, and primary peritoneal carcinoma.
PMID 16769104·Gynecol Oncol·2006
8-other
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
PMID 16896006·J Clin Oncol·2006
3-trial
Ovarian cancer. Clinical practice guidelines in oncology.
PMID 17020669·J Natl Compr Canc Netw·2006
6-review
Rational use of cytotoxic chemotherapy for recurrent ovarian cancer.
PMID 17020671·J Natl Compr Canc Netw·2006
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 44 BINNEY STREET, DANA FARBER CANCER INSTITUTE
BOSTON, MA 02115 - Phone
- (617) 632-2334
Quick Facts
- NPI
- 1992870638
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 39
- Publications
- 20
Are you this provider?
Claim Your Profile